Elsevier

Peptides

Volume 14, Issue 3, May–June 1993, Pages 497-503
Peptides

Article
Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome

https://doi.org/10.1016/0196-9781(93)90138-7Get rights and content

Abstract

Prader-Willi syndrome is characterized by dramatic hyperphagia and morbid obesity, and is associated with a deficiency in basal and meal-stimulated serum pancreatic polypeptide (PP) levels. Intravenous infusions of pancreatic polypeptide (90 min, 50 pmol/kg/h) restored normal serum PP levels, and a regimen of morning and afternoon PP infusions was found to significantly reduce food intake in Prader-Willi subjects. Food intake was evaluated in a 60-min free-feeding test that shows high reliability and validity. Basal food intake during saline infusions was striking (≈60 chicken sandwich quarters), and this intake was reduced overall by ≈12% during PP infusions. This reduction was apparent only for female subjects, and may have reflected enhanced satiation rather than an overall suppression of food intake. No differences were apparent across subjects, in either basal food intake or the PP-related decrease in food intake, in the presence or absence of the widely recognized chromosomal marker for this syndrome [deletion of 15(q11–q13)]. More specific gene defects as recently reported in these subjects, however, suggest that the Prader-Willi syndrome may represent an important model for the study of food intake regulation.

References (53)

  • I.L. Taylor et al.

    Effects of vagotomy on satiety induced by gastrointestinal hormones in the rat

    Physiol. Behav.

    (1985)
  • A.M. Uhe et al.

    Potential regulators of feeding behavior in anorexia nervosa

    Am. J. Clin. Nutr.

    (1992)
  • O. Wisen et al.

    Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal

    Regul. Pept.

    (1992)
  • W.B. Zipf et al.

    Characteristics of abnormal food-intake patterns in children with Prader Willi syndrome and a study of the effects of naloxone

    Am. J. Clin. Nutr.

    (1987)
  • W.B. Zipf et al.

    Short-term infusion of pancreatic polypeptide: Effect on children with Prader-Willi syndrome

    Am. J. Clin. Nutr.

    (1990)
  • C.J. Billington et al.

    Are peptides truly satiety agents? A method of testing for neurohumoral satiety effects

    Am. J. Physiol.

    (1993)
  • G.A. Bray et al.

    The Prader-Willi syndrome: A case study of 40 patients and a review of the literature

    Medicine

    (1983)
  • M.G. Butler

    Prader-Willi syndrome: Current understanding of causes and diagnosis

    Am. J. Med. Genet.

    (1990)
  • M.L. Caldwell et al.

    A clinical note on food preference of individuals with Prader-Willi syndrome: The need for empirical research

    J. Ment. Defic. Res.

    (1983)
  • S.B. Cassidy

    Prader-Willi syndrome

    Curr. Probl. Pediatr.

    (1986)
  • D.J. Clarke et al.

    Adults with Prader-Willi syndrome: Abnormalities of sleep and behavior

    J. R. Soc. Med.

    (1989)
  • S.J. Cooper

    Benzodiazepines, appetite and stress

  • R.J. Gates et al.

    The ability of pancreatic polypeptide (APP and BPP) to return to normal the hyperglycaemia, hyperin-sulinaemia and weight gain in New Zealand obese mice

    Horm. Res.

    (1977)
  • B. Glaser et al.

    Pancreatic polypeptide response to secretin in obesity: Effects of glucose intolerance

    Horm. Metab. Res.

    (1988)
  • L.R. Greenswag

    Adults with Prader-Willi syndrome: A survey of 232 cases

    Dev. Med. Child. Neurol.

    (1987)
  • J.G. Hall

    Genomic imprinting: Review and relevance to human diseases

    Am. J. Hum. Genet.

    (1990)
  • Cited by (119)

    • Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes

      2023, Peptides
      Citation Excerpt :

      Accordingly, peripheral administration of PP results in reduced energy intake in rodents [61] and healthy humans [7]. Indeed, a blunted PP secretion was first observed in obese hyperphagic Prader-Willi patients [108] with exogenous PP application able to reduce food intake in these patients [9]. Furthermore, in people with bulimia nervosa, reduced circulating levels of PP in response to food ingestion are observed [69], whilst in anorexia nervosa plasma PP concentrations are elevated [25], which likely contributes to the pathophysiology of these disorders in humans.

    • Pancreatic Hormones

      2020, Hormonal Signaling in Biology and Medicine: Comprehensive Modern Endocrinology
    • Pancreatic Hormones

      2019, Hormonal Signaling in Biology and Medicine: Comprehensive Modern Endocrinology
    View all citing articles on Scopus
    View full text